WO2011022489A3 - Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles - Google Patents

Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles Download PDF

Info

Publication number
WO2011022489A3
WO2011022489A3 PCT/US2010/045903 US2010045903W WO2011022489A3 WO 2011022489 A3 WO2011022489 A3 WO 2011022489A3 US 2010045903 W US2010045903 W US 2010045903W WO 2011022489 A3 WO2011022489 A3 WO 2011022489A3
Authority
WO
WIPO (PCT)
Prior art keywords
bis
lysine
urea
epigenic
modulators
Prior art date
Application number
PCT/US2010/045903
Other languages
English (en)
Other versions
WO2011022489A2 (fr
Inventor
Robert A. Casero
Patrick M. Woster
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to EP10810552A priority Critical patent/EP2467359A4/fr
Priority to US13/391,247 priority patent/US9708255B2/en
Priority to AU2010284221A priority patent/AU2010284221B2/en
Publication of WO2011022489A2 publication Critical patent/WO2011022489A2/fr
Publication of WO2011022489A3 publication Critical patent/WO2011022489A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention porte sur de nouveaux composés (bis)urée et (bis)thiourée qui sont des inhibiteurs de la déméthylase 1 spécifique à la lysine (LSD1). De tels composés peuvent être utilisés pour traiter des troubles, y compris le cancer.
PCT/US2010/045903 2009-08-18 2010-08-18 Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles WO2011022489A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10810552A EP2467359A4 (fr) 2009-08-18 2010-08-18 Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
US13/391,247 US9708255B2 (en) 2009-08-18 2010-08-18 (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
AU2010284221A AU2010284221B2 (en) 2009-08-18 2010-08-18 (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23479909P 2009-08-18 2009-08-18
US61/234,799 2009-08-18

Publications (2)

Publication Number Publication Date
WO2011022489A2 WO2011022489A2 (fr) 2011-02-24
WO2011022489A3 true WO2011022489A3 (fr) 2011-06-16

Family

ID=43607575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/045903 WO2011022489A2 (fr) 2009-08-18 2010-08-18 Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles

Country Status (4)

Country Link
US (1) US9708255B2 (fr)
EP (1) EP2467359A4 (fr)
AU (1) AU2010284221B2 (fr)
WO (1) WO2011022489A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084160A1 (fr) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
KR101794020B1 (ko) 2010-04-19 2017-11-06 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2012013727A1 (fr) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
WO2012045883A1 (fr) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Inhibiteurs d'oxydases de cyclopropylamine
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
EP2712315B1 (fr) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour des troubles myéloprolifératifs
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012156537A2 (fr) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase destinés au traitement de la thrombose et de maladies cardiovasculaires
WO2012156531A2 (fr) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase destinés au traitement de maladies ou états inflammatoires
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
HUE061252T2 (hu) 2013-12-11 2023-05-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibítorok
ME03580B (fr) 2014-02-13 2020-07-20 Incyte Corp Cyclopropylamines en tant qu'inhibiteurs de lsd1
CA2939082C (fr) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
EP3090998A1 (fr) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Formes solides
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (fr) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
KR102646126B1 (ko) 2016-03-15 2024-03-11 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
CN105801458B (zh) * 2016-03-21 2017-07-21 中南大学 一种醚基双硫氨酯衍生物或醚基双硫脲衍生物及其制备方法和应用
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
SG11201710199PA (en) 2016-06-10 2018-05-30 Oryzon Genomics Sa Methods of treating multiple sclerosis
EP3535420A1 (fr) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarqueurs pour déterminer la sensibilité à des inhibiteurs de lsd1
EP3551178A1 (fr) 2016-12-09 2019-10-16 Constellation Pharmaceuticals, Inc. Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
KR20190122242A (ko) 2017-04-20 2019-10-29 진힐 바이오테크놀로지 컴퍼니 리미티드 항종양 약물의 제조에서의 스페르민 및 그 유도체의 응용
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
WO2019068326A1 (fr) 2017-10-05 2019-04-11 Université D'aix-Marseille Inhibiteurs de la lsd1 pour le traitement et la prévention de cardiomyopathies
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
BR112021016064A2 (pt) 2019-03-20 2021-10-05 Oryzon Genomics, S.A. Métodos de tratamento do transtorno de personalidade borderline
WO2020188089A1 (fr) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Procédés de traitement d'un trouble d'hyperactivité avec déficit de l'attention au moyen d'inhibiteurs de kdm1a tels que le composé vafidemstat
EP3994280A1 (fr) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarqueurs et procédés pour le traitement personnalisé d'un cancer du poumon à petites cellules au moyen d'inhibiteurs de kdm1a
EP3964204A1 (fr) 2020-09-08 2022-03-09 Université d'Aix-Marseille Composés destinés à être utilisés dans le traitement et la prévention de la fibrose de tissus
DE202023100095U1 (de) 2023-01-10 2023-01-26 Ali Alqahtani Ein System für die grüne Synthese und die biologische Bewertung von neuen Harnstoffanaloga

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486391A (en) * 1981-08-25 1984-12-04 Dainippon Ink And Chemicals, Inc. Separation and recovery of ionic substances by fluorine-containing compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1150045B (de) * 1962-02-21 1963-06-12 Bayer Ag Verfahren zur Verbesserung der Waschechtheiten von Faerbungen und Drucken
WO2006113606A2 (fr) 2005-04-18 2006-10-26 Johns Hopkins University Inhibiteurs de l'histone desacetylase
AU2006279943B2 (en) * 2005-08-10 2012-02-16 The Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2008127734A2 (fr) 2007-04-13 2008-10-23 The Johns Hopkins University Inhibiteurs de la déméthylase spécifique de la lysine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486391A (en) * 1981-08-25 1984-12-04 Dainippon Ink And Chemicals, Inc. Separation and recovery of ionic substances by fluorine-containing compound

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN, R. ET AL.: "Noncovalent Anchoring of Homogeneous Catalysts to Silica Supports with Well-Defined Binding Sites", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 44, 2004, pages 14557 - 14566, XP008152816 *
See also references of EP2467359A4 *
SHARMA, S. K. ET AL.: "(Bis)urea and (Bis)thiourea Inhibitors of Lysine- Specific Demethylase 1 as Epigenetic Modulators", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 14, 22 July 2010 (2010-07-22), pages 5197 - 5212, XP008152814 *
SOOMRO, S. A. ET AL.: "Dendrimers with peripheral stilbene chromophores", TETRAHEDRON, vol. 62, no. 34, 2006, pages 8089 - 8094, XP025002530 *
UCHIDA, S. ET AL.: "Properties of dendritic and cyclic thiourea derivatives as neutral carriers for anion sensors", BUNSEKI KAGAKU, vol. 53, no. 9, 2004, pages 943 - 952, XP008152815 *

Also Published As

Publication number Publication date
US20120322877A1 (en) 2012-12-20
US9708255B2 (en) 2017-07-18
EP2467359A4 (fr) 2013-01-09
AU2010284221A1 (en) 2012-03-08
EP2467359A2 (fr) 2012-06-27
AU2010284221B2 (en) 2016-09-22
WO2011022489A2 (fr) 2011-02-24

Similar Documents

Publication Publication Date Title
WO2011022489A3 (fr) Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
WO2012034116A3 (fr) Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2009000291A1 (en) Inhibitors of mek
IN2012DN03883A (fr)
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX2010007490A (es) Preparacion de derivados de sulfamida.
WO2009137462A3 (fr) Procédés de traitement de troubles cognitifs à l&#39;aide d&#39;inhibiteurs de l&#39;histone désacétylase
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
MX2010007543A (es) Inhibidores de iap.
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
TW200745059A (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810552

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010284221

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010810552

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010284221

Country of ref document: AU

Date of ref document: 20100818

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13391247

Country of ref document: US